Ariceum Therapeutics Launches with €25M Series A
Find out what sets Ariceum Therapetutics apart within the radiopharmaceutical arena in this insightful interview with its CEO Manfred Rüdiger and Tyler Patchen of Endpoint News
Find out what sets Ariceum Therapetutics apart within the radiopharmaceutical arena in this insightful interview with its CEO Manfred Rüdiger and Tyler Patchen of Endpoint News
03 May 2022, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies targeting RNA epigenetic mechanisms, today announces that it has been awarded a Biomedical Catalyst grant by Innovate UK to research and develop new drugs directed against a unique SARS-CoV2 protein utilizing STORM’s proprietary RNA epigenetic platform. Read more…
As many countries continue to pass the peak of COVID-19, Masters Speciality Pharma’s Head of Licensing, Sid Masters believes now is a good time to reflect on the challenges, successes and response of the pharmaceutical industry during the pandemic. Sid writes: Over the past few months we have seen Covid-19 wreak havoc by crippling our […]